The objective of this study is to determine the occurrence and degree of acute skin toxicity in patients receiving radical radiation therapy with preventive application of neoVIDERM compared to patients treated with institutional standard skin care.

Patients will apply NeoVIDERM cream to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. Patients will also perform standard of care skin treatment.

Other: Aveeno cream

Twice a day

Other: Flamazine cream

Twice a day, when there is dry desquamation

Other: NeoVIDERM cream

Three times a day

Active Comparator: Arm A: standard skin care

Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatments. If they develop dry desquamation, they will be asked to apply Flamazine twice a day until dermatitis resolves.

Other: Aveeno cream

Twice a day

Other: Flamazine cream

Twice a day, when there is dry desquamation

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion criteria: For patients receiving radiation to the breast

Patients receiving a dose of at least 50 Gy in 25 fractions with concomitant chemotherapy or treated with the McGill technique.

Patients able to understand and sign an informed consent form.

Patients that do not have active connective tissue disorders.

Patients 18 years or older.

Patients that did not receive any previous radiation.

Patients that do not have any known allergy to any ingredients of the NeoVIDERM cream

Patients need to be able to apply the creams themselves or have help with applying the creams.

Inclusion criteria: For patients receiving radiation to the head and neck

Patients receiving radiotherapy on fields that include both sides of the neck

Patients able to understand and sign an informed consent form.

Patients that do not have active connective tissue disorders.

Patients 18 years or older.

Patients that did not receive any previous radiation.

Patients that do not have any known allergy to any ingredients of the NeoVIDERM cream

Patients need to be able to apply the creams themselves or have help with applying the creams.

Exclusion criteria: For patients receiving radiation to the breast or the head and neck

Patients that have a type V or type VI skin type according to the Fitzpatrick scale (because these patients will likely have less radiodermatitis and if they do, it will be harder to evaluate it).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01701466